Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics Inc (NQ: KRTX )

195.00 -1.88 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 219,537
Open 194.78
Bid (Size) 184.74 (1)
Ask (Size) 208.00 (3)
Prev. Close 196.88
Today's Range 191.17 - 196.76
52wk Range 92.26 - 278.25
Shares Outstanding 34,362,777
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Expectations for Karuna Therapeutics's Future
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
 
Via Benzinga

Performance

YTD
+0.94%
+0.94%
1 Month
-0.76%
-0.76%
3 Month
-11.10%
-11.10%
6 Month
+57.52%
+57.52%
1 Year
+75.58%
+75.58%

More News

Read More
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
5 Analysts Have This to Say About Karuna Therapeutics
Via Benzinga
What 5 Analyst Ratings Have To Say About Karuna Therapeutics
Via Benzinga
Where Karuna Therapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Karuna Therapeutics
Via Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Karuna Therapeutics: Q3 Earnings Insights
Via Benzinga
Why Karuna Therapeutics Shares Are Trading Sharply Lower
Via Benzinga
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
From Karuna Therapeutics, Inc.
Via Business Wire
My 3 Top Biotech Stock Picks for 2023
Via The Motley Fool
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Via Investor's Business Daily
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
12 Analysts Have This to Say About Karuna Therapeutics
Via Benzinga
What 12 Analyst Ratings Have To Say About Karuna Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Via Benzinga
Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
2 On-Fire Biotech Stocks That Are Crushing the Bear Market
Via The Motley Fool
Opportunities In Large Cap Growth And Small Cap
Via Talk Markets
Biotech Stocks Well-Positioned For The Fourth Quarter
Via Talk Markets
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
From PsychoGenics Inc.
Via Business Wire
Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress
From Karuna Therapeutics, Inc.
Via Business Wire
Where Karuna Therapeutics Stands With Analysts
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.